Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

December 14, 2022

Study Completion Date

August 15, 2024

Conditions
Graft-versus-host Disease
Interventions
DRUG

Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention

Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT04503616 - Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention | Biotech Hunter | Biotech Hunter